A Phase 2 Basket Trial of Ulixertinib (BVD-523) in Combination With Hydroxychloroquine in Patients With Advanced GI Malignancies Harboring Mitogen-activated Protein Kinase (MAPK) Pathway Mutations (BVD-523-HCQ)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 25 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Hydroxychloroquine (Primary) ; Ulixertinib (Primary)
Indications Adenocarcinoma; Carcinoma; Cholangiocarcinoma; Colorectal cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Sponsors BioMed Valley Discoveries

Most Recent Events

22 Jul 2024 Status changed from recruiting to discontinued. (Reason the study was stopped: Lack of Enrollment for Remaining Open Baskets)
07 Feb 2024 Planned End Date changed from 19 Jun 2024 to 19 Mar 2025.
07 Feb 2024 Planned primary completion date changed from 6 Mar 2024 to 6 Dec 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight